The conference will include original abstracts for presentation on the latest research on PSMA PET imaging and radioligand therapy. The following abstracts will be presented at the 2025 PSMA & Beyond Conference:
| First Author | Institution | Title |
| Abuzar Moradi Tuchayi | UCSF | Retreatment with 177Lu-PSMA-617 Therapy: A Single Center Experience |
| Alireza Ghodsi | University of Washington | Feasibility of Radium-223 Following Lutetium-177 Prostate-Specific Membrane Antigen- 617 Radioligand (Lu-PSMA) Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Initial Clinical Experience |
| Astoria Tai | University of British Columbia | Theranostic Radiohybrids for PSMA Imaging and Potential Therapy |
| Darek Śmiłowicz | University of Wisconsin-Madison | PSMA Targeted In Situ Vaccination For mCRPC |
| Elmira Yazdani | Iran University of Medical Sciences | Integrating Radiomics, Dosiomics, and Clinical Biomarkers in Regression Models for Absorbed Dose Prediction in [177Lu]Lu-PSMA-617 Radioligand Therapy: Insights from Pre-Treatment [68Ga]Ga-PSMA PET/CT Imaging |
| Ida Sonni | UCLA | Prospective, randomized trial comparing PSMA PET/CT and MRI-guided vs MRI only-guided prostate biopsy for identification of clinically significant prostate cancer |
| Jerome Lozada | University of British Columbia | The Development of 18F-Fluorescent Trifluoroborates PET Tracers |
| Jesus Juarez Casillas | UCLA | Dosimetry of Actinium-225-PSMA-I&T in patients with metastatic castrate resistant prostate cancer: insights derived from extrapolation of Lutetium-177-PSMA-I&T |
| Jiarou Wang | Peking Union Medical College Hospital, China | A Dose-Escalation Study of the Novel PSMA-Targeting Drug [177Lu]Lu-P17-088 in Patients with Metastatic Castration-Resistant Prostate Cancer |
| Jiarou Wang | Peking Union Medical College Hospital, China | PSMA-Bisphosphonate Imaging Agent: First Human Study of [68Ga]Ga-P17-079 in Prostate Cancer |
| Katelyn Niknam | VA Greater Los Angeles | Effectiveness of Post-Therapy Imaging in Identifying Extravasation During 177Lu-PSMA-Targeted Radioligand Therapy |
| Kevin H. Leung | John Hopkins, Baltimore, MD | Artificial intelligence-derived PSMA PET/CT biomarkers predict overall survival and progression-free survival in prostate cancer |
| Koichiro Kimura | UCLA | Evaluation of PSMA PET/CT Derived Predictors For Treatment Response to [177Lu]Lu-PSMA-617: Results from The U.S. Expanded-Access Program |
| Laura Forner | University Hospital Essen, Germany | Prostate cancer risk groups by PSMA-PET and PROMISE (PPP): An international multi-center registry study |
| Lena M. Unterrainer | LMU Munich, BZKF, UCLA | Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer |
| Linus Hempel | LMU Munich, Germany | Quantifying total tumor volume on post-treatment 177Lu-PSMA SPECT in mCRPC patients as a potential early response biomarker in a single center retrospective study |
| Luke Nordquist | XCancer, Omaha, NE | COBRA: Assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology as a reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy |
| Magdalena Schöll | LMU Munich | Xerostomia trends reported by FACT-RNT in mCRPC patients under [177Lu]Lu-PSMA-617 radiopharmaceutical therapy and salivary gland dosimetry– a preliminary retrospective analysis |
| Moein Moradpour | UCSF | Quantitative Assessment of Osseous Tumor Burden and Its Correlation with Hematologic Toxicity in Metastatic Prostate Cancer Patients Undergoing PSMA Radioligand Therapy |
| Nouran R. R. Zaid, George Sgouros | John Hopkins | Mathematical Modeling to Optimize Tumor Reduction in [177Lu]Lu-PSMA Therapy |
| Paul Pata-Lavigne | Caribbean Institute of Nuclear Imaging, Martinique | The potential role of 18F PSMA PET/MRI to target prostate cancer in patients with suspicions of prostate cancer and negative biopsy |
| Piyush Aggarwal | PGIMER, Chandigarh, India | Preliminary results of 177Lu-PSMA-617 priming with Enzalutamide in Metastatic Castration-resistant Prostate Cancer: A Single-arm Phase 2 trial (Lu-PRIME) |
| Rafael Sá e Silva | Unidade Local de Saúde de Santo António, Porto, Portugal | [177Lu]Lu-PSMA radioligand therapy in a case of prostate cancer with diffuse bone involvement: clinical challenges and theranostic characterization |
| Rahman Akinlusi | Icahn School of Medicine at Mount Sinai, New York | Genomic Profiling and Treatment Response in Metastatic Castration-Resistant Prostate Cancer Patients Treated with 177Lu-PSMA-617 (Pluvicto) |
| Ruiyue Zhao | Guangzhou Medical University, China | Escalating Dose Radioligand Therapy with [177Lu]Lu-P17-087 in Metastatic Castration-Resistant Prostate Cancer Patients |
| Sara Kurkowska | BC Cancer Research Institute | First in human evaluation of 177Lu-HTK03170: Biodistribution and dosimetry in patients with mCRPC |
| Sara Kurkowska | BC Cancer Research Institute | Comparison of Extrapolation Methods for Animal-to-Human Dosimetry of PSMA targeting agents: 177Lu-HTK03170 and 177Lu-PSMA-617 |
| Sobia Khan | St Vincent's Hospital, Sydney, Australia | Fractionating high short-interval first dose 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: PSMA up-regulation, safety and Efficacy (submitting table separately) |
| Surekha Yadav | UCSF | Patterns of Progression in Patients During 177Lu-PSMA-617 Radioligand Therapy |
| Valentina Marulanda-Corzo | Weill Cornell, New York | PSMA-Targeted Actinium-225 Therapy in Metastatic Castration-Resistant Prostate Cancer: Integrating Imaging Biomarkers with Clinical Outcomes in Monotherapy vs. Combination Therapy |
| Vinicius Ludwig | UCLA | Gastro-intestinal LuPSMA scintigraphy uptake patterns and dosimetry in patients with metastatic prostate cancer treated with LuPSMA: a single center retrospective study |
| Vinicius Ludwig, Adrien Holzgreve | UCLA | Diagnostic performance of 99mTc-Sestamibi SPECT/CT for the characterization of solid renal masses with histopathology standard of truth: a single center retrospective study |
| Vishnu Murthy | UCLA | PSMA PET vs. Pelvic MRI in Biochemically Recurrent Prostate Cancer |
| Vivian S Tan | Western University, Ontario, Canada | Association of Socioeconomic Status and PSMA-PET in Prostate Cancer: An Analysis of the Ontario PSMA-PET Registry for Recurrent Prostate Cancer (PREP) Registry |
| Wen (Jess) Li | Roswell Park Comprehensive Cancer Center | Developing Novel PSMA-Targeted miR34 Therapeutics to Treat Castration-Resistant Prostate Cancer |
| Wendelyn Shanel G. Lim | St. Luke’s Medical Center, Taguig City, Philippines | Role of Post-Therapy SPECT/CT in Detecting Pseudoprogression during Lu-177 PSMA Radioligand Therapy: A Case Report |
| Wesley R. Armstron | UCLA | Post PSMA-PET Outcomes from an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis |
| Yeagyeong Hwang | University of California, Irvine | Prostate Cancer Positive versus Negative Surgical Margins: Assessment of Local and Metastatic Recurrences Using PSMA PET/CT Scans |
| Zachary Ells | LMU Munich, UCLA | Nephroprotective effects of Metformin in patients undergoing radioligand therapy |
| Zachary Ells | LMU Munich, UCLA | Investigation of iterative deconvolution in 177Lu-SPECT imaging for lesion dosimetry |
For poster presentation inquiries please email [email protected].
